|
US2475569A
(en)
|
1944-02-07 |
1949-07-05 |
American Cyanamid Co |
Substituted pyridine compound
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
|
KR20070087266A
(ko)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
피아이-3 키나아제 억제제 프로드러그
|
|
CN1832939B
(zh)
|
2003-05-30 |
2010-04-28 |
杰明X医药品加拿大公司 |
用于治疗癌症或病毒病的三杂环化合物、组合物和方法
|
|
US7129260B2
(en)
*
|
2003-06-02 |
2006-10-31 |
Abbott Laboratories |
Isoindolinone kinase inhibitors
|
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
|
SI2612862T1
(sl)
|
2004-05-13 |
2017-04-26 |
Icos Corporation |
Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
|
|
GB0419160D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
WO2006112479A1
(ja)
*
|
2005-04-19 |
2006-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
含窒素複素環化合物
|
|
EP1888550B1
(en)
|
2005-05-12 |
2014-06-25 |
AbbVie Bahamas Ltd. |
Apoptosis promoters
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
CN103626742B
(zh)
|
2005-11-01 |
2017-04-26 |
塔格根公司 |
激酶的联-芳基间-嘧啶抑制剂
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
JPWO2008047831A1
(ja)
|
2006-10-17 |
2010-02-25 |
協和発酵キリン株式会社 |
Ｊａｋ阻害剤
|
|
HRP20151386T1
(hr)
|
2007-03-12 |
2016-02-26 |
Ym Biosciences Australia Pty Ltd |
Fenil aminopirimidinski spojevi i njihova primjena
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
JP5583592B2
(ja)
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ｉｄｏ阻害剤
|
|
GB0724342D0
(en)
|
2007-12-13 |
2008-01-30 |
Prolysis Ltd |
Anitbacterial compositions
|
|
SG10201408158SA
(en)
|
2008-01-03 |
2015-03-30 |
Univ Aix Marseille |
Composition and methods used during anti-hiv treatment
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
|
PH12012500881A1
(en)
|
2009-12-10 |
2017-07-26 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
US8314120B2
(en)
|
2010-03-30 |
2012-11-20 |
Abbott Gmbh & Co. Kg |
Small molecule potentiators of metabotropic glutamate receptors
|
|
MX378336B
(es)
|
2010-05-04 |
2025-03-10 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
NO2694640T3
(https=)
|
2011-04-15 |
2018-03-17 |
|
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
WO2013086397A1
(en)
|
2011-12-08 |
2013-06-13 |
Array Biopharma Inc. |
Urea compounds as gka activators
|
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
|
RU2014136332A
(ru)
|
2012-02-06 |
2016-03-27 |
Дженентек, Инк. |
Композиции и способы применения ингибиторов csf1r
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9315494B2
(en)
|
2012-11-08 |
2016-04-19 |
Bristol-Myers Squibb Company |
Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
|
|
MY194668A
(en)
|
2012-11-08 |
2022-12-12 |
Bristol Myers Squibb Co |
Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
|
|
EP3080131B1
(en)
|
2013-12-10 |
2018-10-10 |
Bristol-Myers Squibb Company |
Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
DK3212637T3
(da)
*
|
2014-10-31 |
2021-07-12 |
Indivior Uk Ltd |
Dopamin-d3-receptorantagonistforbindelser
|
|
WO2016101119A1
(en)
|
2014-12-23 |
2016-06-30 |
Merck Sharp & Dohme Corp. |
Fused heteroaryl derivatives as orexin receptor antagonists
|
|
KR101660863B1
(ko)
*
|
2015-04-03 |
2016-09-28 |
주식회사 녹십자 |
IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
|
|
KR101846475B1
(ko)
*
|
2015-04-27 |
2018-04-09 |
주식회사 녹십자 |
TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
|
|
RS61919B1
(sr)
*
|
2015-06-25 |
2021-06-30 |
Univ Health Network |
Inhibitori hpk1 i postupci za njihovo korišćenje
|
|
CN108699077B
(zh)
|
2016-01-15 |
2021-03-02 |
英安塔制药有限公司 |
作为rsv抑制剂的杂环化合物
|
|
US20190119236A1
(en)
*
|
2016-02-23 |
2019-04-25 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
|
TW201811799A
(zh)
|
2016-09-09 |
2018-04-01 |
美商英塞特公司 |
吡唑并嘧啶化合物及其用途
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
US11180482B2
(en)
|
2016-11-30 |
2021-11-23 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
|
|
EP3555064B9
(en)
|
2016-12-16 |
2023-03-01 |
Pfizer Inc. |
Glp-1 receptor agonists and uses thereof
|
|
MX2019011511A
(es)
|
2017-03-30 |
2019-11-18 |
Hoffmann La Roche |
Naftiridinas como inhibidores de cinasa 1 progenitora hematopoyetica (hpk1).
|
|
CN109721620B
(zh)
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
JP7167146B2
(ja)
*
|
2017-11-06 |
2022-11-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｈｐｋ１阻害剤として有用なイソフラノン化合物
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
WO2019164847A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
DK3873600T5
(da)
|
2018-10-29 |
2024-03-18 |
Boehringer Ingelheim Int |
Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
|
|
US11142525B2
(en)
*
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
|
CN114945366B
(zh)
|
2019-09-13 |
2025-01-07 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2021262684A1
(en)
|
2020-06-22 |
2021-12-30 |
Pmv Pharmaceuticals, Inc. |
METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
|